Variation in antibody titers determined by Abbott and Roche Elecsys SARS-CoV-2 assays in vaccinated healthcare workers.

Miku Nakai, Daisuke Yokoyama, Tomoaki Sato, Ryohei Sato, Chiari Kojima, Tatsuo Shimosawa

Abstract read

In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients.Scientific reports · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miku NakaiDepartment of Clinical Laboratory, International University of Health and Welfare Narita Hospital, Chiba, Japan.

Daisuke YokoyamaDepartment of Clinical Laboratory, International University of Health and Welfare Mita Hospital, Tokyo, Japan.

Tomoaki SatoDepartment of Clinical Laboratory, International University of Health and Welfare Narita Hospital, Chiba, Japan.

Ryohei SatoDepartment of Clinical Laboratory, International University of Health and Welfare Mita Hospital, Tokyo, Japan.

Chiari KojimaDepartment of Clinical Laboratory, International University of Health and Welfare Mita Hospital, Tokyo, Japan.

Tatsuo ShimosawaDepartment of Clinical Laboratory, International University of Health and Welfare Narita Hospital, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2-specific antibody measurement is important for evaluating COVID-19 vaccine efficacy. We quantified and compared anti-spike (S) antibodies using different commercial immunoassays. We tested serum samples from 70 SARS-CoV-2-naive health care workers 2 weeks after vaccination with a single dose of BNT162b2, 2 and 4 weeks, and 3 months after the second dose of BNT162b2. The following quantitative assays were used: Roche Elecsys

Indexed as

AntibodyBNT-162b2 vaccineImmunoassaysImmunological responseSARS-CoV-2

Identifiers

PMID37235203

DOI10.1016/j.heliyon.2023.e16547

PMCPMC10201891

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.